Juliet Elizabeth Wolford, MD, on Ovarian Cancer: The Cost of Care
2018 ASCO Annual MeetingJuliet Elizabeth Wolford, MD, of the University of California, Irvine, discusses the cost-effectiveness of various types of maintenance therapy in advanced ovarian cancer: paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab (Abstract 5508).
Related Videos
Rebecca A. Dent, MD, on Triple-Negative Breast Cancer: Results From the LOTUS Trial
Rebecca A. Dent, MD, of the National Cancer Centre Singapore, discusses phase II study findings on first-line ipatasertib plus paclitaxel for locally advanced/metastatic triple-neg...
Michael Gnant, MD, on Breast Cancer: Results From the ABCSG-18 Trial
Michael Gnant, MD, of the Medical University of Vienna, discusses study findings on adjuvant denosumab in early breast cancer––a disease-free survival analysis of postmenopausal pa...
Thierry Conroy, MD, on Pancreatic Cancer: Results From the PRODIGE 24 Trial
Thierry Conroy, MD, of the Institut de Cancérologie de Lorraine, discusses phase III study findings on adjuvant mFOLFIRINOX vs gemcitabine in patients with resected pancreatic duct...
Nathan A. Pennell, MD, PhD, on NSCLC: Lowering Genetic Testing Costs
Nathan A. Pennell, MD, PhD, of the Cleveland Clinic, discusses the economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alte...
Helena Margaret Earl, MBBS, PhD, on Early Breast Cancer: Results From the Persephone Trial
Helena Margaret Earl, MBBS, PhD, of the University of Cambridge, discusses phase III study findings on 6 vs 12 months of adjuvant trastuzumab in patients with HER2-positive early b...
